Capricor Therapeutics Inc... (CAPR)
Capricor Therapeutics Statistics
Share Statistics
Capricor Therapeutics has 45.68M shares outstanding. The number of shares has increased by 42.83% in one year.
| Shares Outstanding | 45.68M |
| Shares Change (YoY) | 42.83% |
| Shares Change (QoQ) | 0.45% |
| Owned by Institutions (%) | 52.35% |
| Shares Floating | 40.12M |
| Failed to Deliver (FTD) Shares | 3.36K |
| FTD / Avg. Volume | 0.24% |
Short Selling Information
The latest short interest is 10.67M, so 23.36% of the outstanding shares have been sold short.
| Short Interest | 10.67M |
| Short % of Shares Out | 23.36% |
| Short % of Float | 26.58% |
| Short Ratio (days to cover) | 8.07 |
Valuation Ratios
The PE ratio is -12.01 and the forward PE ratio is 317.25. Capricor Therapeutics's PEG ratio is -0.31.
| PE Ratio | -12.01 |
| Forward PE | 317.25 |
| PS Ratio | 21.82 |
| Forward PS | 1 |
| PB Ratio | 3.34 |
| P/FCF Ratio | -11.7 |
| PEG Ratio | -0.31 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Capricor Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.77, with a Debt / Equity ratio of 0.01.
| Current Ratio | 7.77 |
| Quick Ratio | 7.77 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | -0.04 |
| Debt / FCF | -0.03 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $139.19K |
| Profits Per Employee | $-252.92K |
| Employee Count | 160 |
| Asset Turnover | 0.13 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by 138.09% in the last 52 weeks. The beta is 4.67, so Capricor Therapeutics's price volatility has been higher than the market average.
| Beta | 4.67 |
| 52-Week Price Change | 138.09% |
| 50-Day Moving Average | 12.27 |
| 200-Day Moving Average | 12.28 |
| Relative Strength Index (RSI) | 56.49 |
| Average Volume (20 Days) | 1.4M |
Income Statement
In the last 12 months, Capricor Therapeutics had revenue of 22.27M and earned -40.47M in profits. Earnings per share was -1.15.
| Revenue | 22.27M |
| Gross Profit | 20.85M |
| Operating Income | -42.56M |
| Net Income | -40.47M |
| EBITDA | -41.17M |
| EBIT | -42.56M |
| Earnings Per Share (EPS) | -1.15 |
Balance Sheet
The company has 0 in cash and 1.45M in debt, giving a net cash position of -1.45M.
| Cash & Cash Equivalents | 0 |
| Total Debt | 1.45M |
| Net Cash | -1.45M |
| Retained Earnings | -199.83M |
| Total Assets | 170.48M |
| Working Capital | 64M |
Cash Flow
In the last 12 months, operating cash flow was -40M and capital expenditures 0, giving a free cash flow of -41.53M.
| Operating Cash Flow | -40M |
| Capital Expenditures | 0 |
| Free Cash Flow | -41.53M |
| FCF Per Share | -1.18 |
Margins
Gross margin is 93.6%, with operating and profit margins of -191.13% and -181.71%.
| Gross Margin | 93.6% |
| Operating Margin | -191.13% |
| Pretax Margin | -181.71% |
| Profit Margin | -181.71% |
| EBITDA Margin | -184.84% |
| EBIT Margin | -191.13% |
| FCF Margin | -186.5% |
Dividends & Yields
CAPR does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for CAPR is $32.5, which is 156.1% higher than the current price. The consensus rating is "Buy".
| Price Target | $32.5 |
| Price Target Difference | 156.1% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
Stock Splits
The last stock split was on Jun 5, 2019. It was a backward split with a ratio of 1:10.
| Last Split Date | Jun 5, 2019 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | 13.75 |
| Piotroski F-Score | 2 |